Pervasis Therapeutics
Cambridge
About Pervasis Therapeutics
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts ’ the failure of which result in serious complications and a significant increase in medical costs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $42.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2009)
- Website: pervasistx.com
- Phone: +1 617-621-3407
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/pervasis-therapeutics-1299020 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.